From: Coronary aspirate TNFα reflects saphenous vein bypass graft restenosis risk in diabetic patients
With DM | Without DM | P-value | |
---|---|---|---|
demographics | |||
number | 20 | 20 | 1.0 |
gender, female/male | 0/20 | 0/20 | 1.0 |
age [years] | 64±2 | 68±2 | 0.2 |
body height [cm] | 174±1 | 173±1 | 0.5 |
body weight [kg] | 89±2 | 83±2 | 0.04 |
risk factors/comorbidities | |||
hypertension | 20 | 20 | 1.0 |
BMI [kg/m2] | 29.4±0.7 | 27.8±0.6 | 0.1 |
smoking | 1 | 3 | 0.6 |
hypercholesterolemia | 18 | 20 | 0.5 |
family history of CAD | 6 | 5 | 1.0 |
hemodynamics | |||
systolic blood pressure [mmHg] | 129±6 | 134±3 | 0.5 |
diastolic blood pressure [mmHg] | 65±3 | 66±2 | 0.6 |
heart rate [bpm] | 66±2 | 66±3 | 0.9 |
laboratory analysis | |||
total cholesterol [mmol/L] | 4.5±0.3 | 4.5±0.2 | 0.8 |
HDL cholesterol [mmol/L] | 1.0±0.1 | 1.0±0.1 | 0.9 |
LDL cholesterol [mmol/L] | 2.5±0.2 | 2.7±0.2 | 0.4 |
CRP [mg/L] | 5.6±0.9 | 4.8±1.0 | 0.6 |
triglycerides [mmol/L] | 2.7±0.5 | 1.8±0.3 | 0.1 |
serum creatinine [μmol/L] | 114.0±6.4 | 111.8±4.4 | 0.8 |
urea nitrogen [mmol/L] | 8.0±1.2 | 7.7±0.6 | 0.9 |
eGFR [mL/min/1.73 m2] | 60.1±2.9 | 59.7±3.0 | 0.9 |
HbA1c [%] | 7.7±0.3 | 5.3±0.2 | < 0.01 |
medication | |||
ACE inhibitors | 19 | 15 | 0.2 |
AT1-receptor antagonists | 3 | 4 | 1.0 |
beta-blockers | 19 | 18 | 1.0 |
calcium antagonists | 3 | 1 | 0.6 |
statins | 19 | 18 | 1.0 |
diuretics | 18 | 10 | 0.01 |
antidiabetics: | 16 | 0 | < 0.01 |
metformin | 13 | 0 | 0.05 |
glibenclamide | 3 | 0 | 0.6 |
insulin | 5 | 0 | 0.05 |
aspirin | 20 | 20 | 1.0 |
clopidogrel | 17 | 17 | 1.0 |